Cargando…

Independent prognostic value of fascin immunoreactivity in stage III–IV colonic adenocarcinoma

Fascin, an actin-bundling protein involved in cell motility, has been shown to be upregulated in several types of carcinomas. In this study, we investigated the expression of fascin in 228 advanced colonic adenocarcinoma patients with a long follow-up. Fascin expression was compared with several cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Puppa, G, Maisonneuve, P, Sonzogni, A, Masullo, M, Chiappa, A, Valerio, M, Zampino, M G, Franceschetti, I, Capelli, P, Chilosi, M, Menestrina, F, Viale, G, Pelosi, G
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360113/
https://www.ncbi.nlm.nih.gov/pubmed/17375048
http://dx.doi.org/10.1038/sj.bjc.6603690
_version_ 1782152967630094336
author Puppa, G
Maisonneuve, P
Sonzogni, A
Masullo, M
Chiappa, A
Valerio, M
Zampino, M G
Franceschetti, I
Capelli, P
Chilosi, M
Menestrina, F
Viale, G
Pelosi, G
author_facet Puppa, G
Maisonneuve, P
Sonzogni, A
Masullo, M
Chiappa, A
Valerio, M
Zampino, M G
Franceschetti, I
Capelli, P
Chilosi, M
Menestrina, F
Viale, G
Pelosi, G
author_sort Puppa, G
collection PubMed
description Fascin, an actin-bundling protein involved in cell motility, has been shown to be upregulated in several types of carcinomas. In this study, we investigated the expression of fascin in 228 advanced colonic adenocarcinoma patients with a long follow-up. Fascin expression was compared with several clinicopathologic parameters and survival. Overall, fascin immunoreactivity was detected in 162 (71%) tumours with a prevalence for right-sided tumours (P<0.001). Fascin correlated significantly with sex, tumour grade and stage, mucinous differentiation, number of metastatic lymph nodes, extranodal tumour extension, and the occurrence of distant metastases. Patients with fascin-expressing tumours experienced a shorter disease-free and overall survival in comparison with those with negative tumours, and fascin immunoreactivity emerged as an independent prognostic factor in the multivariate analysis. Moreover, patients with the same tumour stages could be stratified in different risk categories for relapse and progression according to fascin expression. Our findings suggest that fascin is a useful prognostic marker for colonic adenocarcinomas.
format Text
id pubmed-2360113
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23601132009-09-10 Independent prognostic value of fascin immunoreactivity in stage III–IV colonic adenocarcinoma Puppa, G Maisonneuve, P Sonzogni, A Masullo, M Chiappa, A Valerio, M Zampino, M G Franceschetti, I Capelli, P Chilosi, M Menestrina, F Viale, G Pelosi, G Br J Cancer Molecular Diagnostics Fascin, an actin-bundling protein involved in cell motility, has been shown to be upregulated in several types of carcinomas. In this study, we investigated the expression of fascin in 228 advanced colonic adenocarcinoma patients with a long follow-up. Fascin expression was compared with several clinicopathologic parameters and survival. Overall, fascin immunoreactivity was detected in 162 (71%) tumours with a prevalence for right-sided tumours (P<0.001). Fascin correlated significantly with sex, tumour grade and stage, mucinous differentiation, number of metastatic lymph nodes, extranodal tumour extension, and the occurrence of distant metastases. Patients with fascin-expressing tumours experienced a shorter disease-free and overall survival in comparison with those with negative tumours, and fascin immunoreactivity emerged as an independent prognostic factor in the multivariate analysis. Moreover, patients with the same tumour stages could be stratified in different risk categories for relapse and progression according to fascin expression. Our findings suggest that fascin is a useful prognostic marker for colonic adenocarcinomas. Nature Publishing Group 2007-04-10 2007-03-20 /pmc/articles/PMC2360113/ /pubmed/17375048 http://dx.doi.org/10.1038/sj.bjc.6603690 Text en Copyright © 2007 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Molecular Diagnostics
Puppa, G
Maisonneuve, P
Sonzogni, A
Masullo, M
Chiappa, A
Valerio, M
Zampino, M G
Franceschetti, I
Capelli, P
Chilosi, M
Menestrina, F
Viale, G
Pelosi, G
Independent prognostic value of fascin immunoreactivity in stage III–IV colonic adenocarcinoma
title Independent prognostic value of fascin immunoreactivity in stage III–IV colonic adenocarcinoma
title_full Independent prognostic value of fascin immunoreactivity in stage III–IV colonic adenocarcinoma
title_fullStr Independent prognostic value of fascin immunoreactivity in stage III–IV colonic adenocarcinoma
title_full_unstemmed Independent prognostic value of fascin immunoreactivity in stage III–IV colonic adenocarcinoma
title_short Independent prognostic value of fascin immunoreactivity in stage III–IV colonic adenocarcinoma
title_sort independent prognostic value of fascin immunoreactivity in stage iii–iv colonic adenocarcinoma
topic Molecular Diagnostics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360113/
https://www.ncbi.nlm.nih.gov/pubmed/17375048
http://dx.doi.org/10.1038/sj.bjc.6603690
work_keys_str_mv AT puppag independentprognosticvalueoffascinimmunoreactivityinstageiiiivcolonicadenocarcinoma
AT maisonneuvep independentprognosticvalueoffascinimmunoreactivityinstageiiiivcolonicadenocarcinoma
AT sonzognia independentprognosticvalueoffascinimmunoreactivityinstageiiiivcolonicadenocarcinoma
AT masullom independentprognosticvalueoffascinimmunoreactivityinstageiiiivcolonicadenocarcinoma
AT chiappaa independentprognosticvalueoffascinimmunoreactivityinstageiiiivcolonicadenocarcinoma
AT valeriom independentprognosticvalueoffascinimmunoreactivityinstageiiiivcolonicadenocarcinoma
AT zampinomg independentprognosticvalueoffascinimmunoreactivityinstageiiiivcolonicadenocarcinoma
AT franceschettii independentprognosticvalueoffascinimmunoreactivityinstageiiiivcolonicadenocarcinoma
AT capellip independentprognosticvalueoffascinimmunoreactivityinstageiiiivcolonicadenocarcinoma
AT chilosim independentprognosticvalueoffascinimmunoreactivityinstageiiiivcolonicadenocarcinoma
AT menestrinaf independentprognosticvalueoffascinimmunoreactivityinstageiiiivcolonicadenocarcinoma
AT vialeg independentprognosticvalueoffascinimmunoreactivityinstageiiiivcolonicadenocarcinoma
AT pelosig independentprognosticvalueoffascinimmunoreactivityinstageiiiivcolonicadenocarcinoma